Author:
Hartl Christina A.,Bertschi Adrian,Puerto Regina Bou,Andresen Carolin,Cheney Emily M.,Mittendorf Elizabeth A.,Guerriero Jennifer L.,Goldberg Michael S.
Funder
Ovarian Cancer Research Fund
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference53 articles.
1. ACS. Cancer Facts & Figures. Atlanta: American Cancer Society; 2018.
2. ORCFA. Statistics: Ovarian Cancer Resarch Fund Alliance, New York, New York, USA; 2018
3. du Bois A, Luck HJ, Bauknecht T, Mobus V, Bochtler H, Diergarten K, et al. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol. 1997;8:355–61.
4. Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I. A systematic review of ovarian Cancer and fear of recurrence. Palliat Support Care. 2015;13:1771–80.
5. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–43.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献